GlaxoSmithKline (GSKN) Stock Statistics & Valuation Metrics
Total Valuation
GlaxoSmithKline has a market cap or net worth of MXN 1.87T. The enterprise value is MXN 125.13B.
- Market Cap
- MXN 1.87T
- Enterprise Value
- MXN 125.13B
Share Statistics
GlaxoSmithKline has 2,022,715,300 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 2,022,715,300
- Owned by Insiders
- ―
- Owned by Institutions
- 6.95%
Financial Efficiency
GlaxoSmithKline’s return on equity (ROE) is 0.35 and return on invested capital (ROIC) is 16.61%.
- Return on Equity (ROE)
- 0.35
- Return on Assets (ROA)
- 0.09
- Return on Invested Capital (ROIC)
- 16.61%
- Return on Capital Employed (ROCE)
- 0.21
- Revenue Per Employee
- 488.73K
- Profits Per Employee
- 85.52K
- Employee Count
- 66,841
- Asset Turnover
- 0.54
- Inventory Turnover
- 1.52
Valuation Ratios
The current PE Ratio of GlaxoSmithKline is 17.18. GlaxoSmithKline’s PEG ratio is -0.83.
- PE Ratio
- 17.18
- PS Ratio
- 2.22
- PB Ratio
- 3.97
- Price to FCF
- 10.87
- Price to Operating Cash Flow
- 8.69
- PEG Ratio
- -0.83
Income Statement
In the last 12 months, GlaxoSmithKline had revenue of 32.67B and earned 5.72B in profits. Earnings per share was 2.82.
- Revenue
- 32.67B
- Gross Profit
- 23.65B
- Operating Income
- 8.34B
- Pretax Income
- 7.40B
- Net Income
- 5.72B
- EBITDA
- 10.40B
- Earnings Per Share (EPS)
- 2.82
Cash Flow
In the last 12 months, operating cash flow was 8.50B and capital expenditures -1.70B, giving a free cash flow of 6.79B billion.
- Operating Cash Flow
- 8.50B
- Free Cash Flow
- 6.79B
- Free Cash Flow per Share
- 3.41
Dividends & Yields
GlaxoSmithKline pays an annual dividend of ―, resulting in a dividend yield of 3.38%
- Dividend Per Share
- ―
- Dividend Yield
- 3.38%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 9.20%
- Earnings Yield
- 5.85%
Stock Price Statistics
- Beta
- 0.21
- 52-Week Price Change
- 8.35%
- 50-Day Moving Average
- 865.95
- 200-Day Moving Average
- 917.76
- Relative Strength Index (RSI)
- 89.21
- Average Volume (3m)
- 46
Important Dates
GlaxoSmithKline upcoming earnings date is Feb 03, 2027, Before Open (Not Confirmed).
- Last Earnings Date
- Oct 28, 2026
- Next Earnings Date
- Feb 03, 2027
- Ex-Dividend Date
- ―
Financial Position
GlaxoSmithKline as a current ratio of 0.82, with Debt / Equity ratio of 108.20%
- Current Ratio
- 0.82
- Quick Ratio
- 0.54
- Debt to Market Cap
- 0.24
- Net Debt to EBITDA
- 1.37
- Interest Coverage Ratio
- 12.14
Taxes
In the past 12 months, GlaxoSmithKline has paid 1.11B in taxes.
- Income Tax
- 1.11B
- Effective Tax Rate
- 0.15
Enterprise Valuation
GlaxoSmithKline EV to EBITDA ratio is 8.94, with an EV/FCF ratio of 13.91.
- EV to Sales
- 2.84
- EV to EBITDA
- 8.94
- EV to Free Cash Flow
- 13.91
- EV to Operating Cash Flow
- 11.11
Balance Sheet
GlaxoSmithKline has MXN 2.98B in cash and marketable securities with MXN 23.86B in debt, giving a net cash position of -MXN 20.88B billion.
- Cash & Marketable Securities
- MXN 2.98B
- Total Debt
- MXN 23.86B
- Net Cash
- -MXN 20.88B
- Net Cash Per Share
- -MXN 10.32
- Tangible Book Value Per Share
- -MXN 7.55
Margins
Gross margin is 73.52%, with operating margin of 23.80%, and net profit margin of 12.97%.
- Gross Margin
- 73.52%
- Operating Margin
- 23.80%
- Pretax Margin
- 16.05%
- Net Profit Margin
- 12.97%
- EBITDA Margin
- 31.72%
- EBIT Margin
- 25.11%
Analyst Forecast
The average price target for GlaxoSmithKline is MXN 1,156.46, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- MXN 1,156.46
- Price Target Upside
- 23.29% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 3
- Revenue Growth Forecast
- -3.91%
- EPS Growth Forecast
- -26.26%
Scores
- Smart Score
- 6
- AI Score
- ―
